Finally, the clinical outcome in metastatic melanoma patients exhibiting low (20th percentile, medium (between the 20th and 80th percentile), high (80th percentile) SGMS1, SGMS2, and UGCG expression was analyzed in the TCGA cohort. Here, SGMS2 is linked to metastatic melanoma.